Abstract
Dendritic cells (DCs) are professional antigen-presenting cells that play an important role in both innate and acquired immune responses against pathogens. However, the role of DCs in coronavirus disease 2019 (COVID-19) is unclear. Virus-like particles (VLPs) that structurally mimic the original virus are one of the candidates COVID-19 vaccines. In the present study, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) VLPs were used as an alternative to live virus to evaluate the interaction of the virus with DCs. The results revealed that SARS-CoV-2 VLPs induced DC maturation by augmenting cell surface molecule expression (CD80, CD86, and major histocompatibility complex class II (MHC-II)) and inflammatory cytokine production (tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and IL-12p70) in DCs via the mitogen-activated protein kinase and nuclear factor-κB signaling pathways. In addition, mature DCs induced by SARS-CoV-2 VLPs promoted T cell proliferation, which was dependent on VLPs concentration. Our results suggest that SARS-CoV-2 VLPs regulate the immune response by interacting with DCs. These findings will improve the understanding of SARS-CoV-2 pathogenesis and SARS-CoV-2 vaccine development.
Introduction
Dendritic cells (DCs), which are professional antigen-presenting cells, play a vital role in both innate and acquired immune responses against pathogens (Stockwin et al., 2000). According to their phenotypic and functional characteristics, DCs are classified into immature and mature DCs (Sousa, 2006). Immature DCs capture and internalize pathogens via pattern recognition receptors (Banchereau et al., 2000), and after interaction with infectious agents, immature DCs mature. Mature DCs lose endocytic/phagocytic receptors and express higher levels of surface molecules such as CD80, CD86, and major histocompatibility complex class II (MHC-II) as well as several cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-12, and IL-6 (Lee et al., 2014). Moreover, these mature DCs transport antigens to the lymph nodes for activating naive T cells (Sousa, 2022).
Preliminary studies suggest that DCs play an essential role in human coronavirus outbreaks. Yoshikawa et al. reported that severe acute respiratory syndrome coronavirus (SARS-CoV) induced DCs to express CD40 and CD86 and secrete cytokines (Yilla et al., 2005; Yoshikawa et al., 2009). One study revealed that Middle East respiratory syndrome coronavirus (MERS-CoV) could infect DCs, upregulate the expression of surface molecules on infected DCs, and induce higher expression of cytokines and chemokines in DCs infected by MERS-CoV than by SARS-CoV (Chu et al., 2014). SARS-CoV-2 invades cells via angiotensin-converting enzyme 2 and leads to a cytokine storm, leading to disease progression (Hoffmann et al., 2020). DCs, macrophages, neutrophils, and other immune cells are involved in the pathogenesis of coronavirus disease 2019 (COVID-19) (Mangalmurti and Hunter, 2020). Xiong et al. analyzed the transcriptomic characteristics of bronchoalveolar lavage fluid from patients with COVID-19 and found a relative increase in the levels of mature DCs (Xiong et al., 2020). The association of COVID-19 severity with the pulmonary redistribution of CD1c+ DCs has been reported (Sánchez-Cerrillo et al., 2020). These studies suggest that DCs participate in the lung response against SARS-CoV-2 infection. At present, the COVID-19 pandemic is still active worldwide, and vaccine and therapeutic development has been the major focus of research. However, the role of DCs in COVID-19 has not been elucidated.
Virus-like particles (VLPs) are nanoscale structures formed by viral structural proteins. VLPs lack genetic material and thus have no infectivity or pathogenicity (Mohsen et al., 2020). Therefore, they can be used as drugs, vaccines, and imaging agents as well as in drug and gene delivery (Roldão et al., 2010; Ma et al., 2012; Chung et al., 2020). VLPs have been shown to be strong DC activators by inducing DC maturation and promoting immune mediator priming based on B and T cells (Zepeda-Cervantes et al., 2020).
Research on live SARS-CoV-2 is restricted to biosafety level (BSL)-3 laboratories. Some highly pathogenic pathogens, including SARS-CoV, MERS-CoV, and Ebola virus, that require BSL-3 or -4 facilities for their handling have adopted VLPs as an alternative model for viruses (Mortola and Roy, 2004; Swenson et al., 2004; Siu et al., 2008; Wang et al., 2017). Plescia et al. established a model of SARS-CoV-2 viral budding and entry using BSL-2-level VLPs (Plescia et al., 2020). The present authors previously produced SARS-CoV-2 VLPs in insect cells using the Bac-to-Bac system (Mi et al., 2021). The VLPs comprised three structural proteins, including the spike (S) protein, the envelope (E) protein, and the membrane (M) protein, of SARS-CoV-2. These VLPs can serve as potential vaccine candidates as well as tools to study SARS-CoV-2 pathogenesis. Herein, SARS-CoV-2 VLPs were used as an alternative to live virus study the immune responses induced in DCs. The phenotypic and functional changes of immature DCs induced by SARS-CoV-2 VLPs were investigated.
Methods
Preparation of SARS-CoV-2 VLPs
The preparation and identification of SARS-CoV-2 VLPs are described previously (Mi et al., 2021). In brief, the codon-optimized S, E, and M genes of SARS-CoV-2 (GenBank accession no. MN908947.3) were cloned into the pFastBac triple expression vector. Recombinant baculovirus was produced using the Bac-to-Bac system (ThermoFisher Scientific, USA). VLPs were then obtained by infecting ExpiSf9™ insect cells with the recombinant baculovirus and purified via density gradient centrifugation.
SARS-CoV-2 VLPs were adsorbed onto a 400-mesh carbon-coated film for 2 min, which was then stained with 1% phosphotungstic acid for 60 s. After staining, VLP morphology was visualized using FEI Talos F200C transmission electron microscope (FEI, Czech Republic). For immunoelectron microscopy, VLPs were captured on carbon-coated copper grids. The grids were incubated with rabbit anti-spike polyclonal antibody (1:50 dilution; SinoBiological, China) at room temperature for 1 h, followed by treatment with goat anti-rabbit immunoglobulin G (1:20 dilution) (whole)-gold conjugate (10 nm) (BOSTER, China). Finally, the negative staining of the grids was performed using 1% phosphotungstic acid. VLPs were observed on the transmission electron microscope (FEI, Czech Republic) at 200 kV and 100–200 kfold magnification.
Production and culture of DCs
DCs were produced using a modified Inaba et al. method (Inaba et al., 1992). In brief, bone marrow cells were collected from the femurs of C57BL/6 mice and lysed using red blood cell lysing buffer (ammonium chloride, 4.15 g/500 mL and 0.01 M Tris-HCl buffer; pH 7.5). The obtained cells were plated in six-well culture plates (1 × 106 cells/mL; 4 mL per well) in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 20 ng/mL recombinant mouse (rm) granulocyte-macrophage colony-stimulating factor, and 10 ng/mL rmIL-4 at 37°C in 5% CO2. At days 3 and 5, half of the medium was replaced with fresh complete RPMI media with cytokines. On day 6, nonadherent cells and loosely adherent cells, which were considered immature DCs (>85% pure), were harvested for analysis or stimulation. All animal experiments were performed under the guidelines of the Council on Animal Care and Use, and the experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Lanzhou University.
Cytotoxicity analysis
To investigate the cytotoxic effect of VLPs on DCs, the isolated DCs were cocultured with 5, 10, or 15 μg/mL VLPs in 12-well plates (5 × 105 cells/mL). After 24, 48, or 72 h of treatment, the harvested DCs were washed with phosphate-buffered saline (PBS) and stained using fluorescein isothiocyanate (FITC)–Annexin V and propidium iodide (Sangon Biotech, China). DC cytotoxicity was then analyzed via flow cytometry (NovoCyte Flow Cytometer, Agilent Technologies Inc., USA).
Measurement of DC proliferation
DCs (5 × 105 cells/mL) were incubated with 5, 10, or 15 μg/mL SARS-CoV-2 VLPs at 100 μL/well in 96-well plates for 24 h. DC proliferation was evaluated using Cell Counting Kit (CCK)-8 assay (BOSTER, China). Optical density at 450 nm (OD450) was measured on a microplate reader. DC proliferation was expressed as the stimulation index (SI). SI was calculated using the following formula: SI = (ODsample well − ODblank well)/(ODnegative well − ODblank well).
Flow cytometric analysis of surface molecule expression
On day 6, DCs were harvested, washed with cold PBS, and supplemented with 0.1% sodium azide. The cells were incubated with 0.5% bovine serum albumin in PBS for 30 min and washed with PBS. They were then stained with FITC-conjugated anti-CD11c, phycoerythrin (PE)-conjugated anti-CD80, anti-CD86, and anti-MHC-II antibodies (ThermoFisher Scientific, USA) at 4°C for 30 min. Cells were washed three times with PBS and resuspended in 500 μL PBS. Fluorescence was measured using flow cytometry, and data were analyzed using Novoexpress software.
Antigen uptake ability of DCs via SARS-CoV-2 VLPs
To evaluate the antigen uptake ability of DCs, 5 × 105 DCs were equilibrated at 37°C or 4°C for 45 min and then pulsed with FITC-conjugated dextran (MW 40,000, Ruixi biological technology, China) at a concentration of 1 mg/mL for 1 h; the reaction was stopped using cold staining buffer. The antigen uptake ability was measured using flow cytometry.
Cytokine assay
TNF-α mouse uncoated enzyme-linked immunosorbent assay (ELISA) kit, IL-1β mouse uncoated ELISA kit, IL-10 mouse uncoated ELISA kit, IL-12 p70 mouse uncoated ELISA kit, interferon (IFN)-γ mouse uncoated ELISA kit, and IL-4 mouse uncoated ELISA kit were purchased from Invitrogen (ThermoFisher Scientific, USA). DCs (5 × 105 cells/mL) were incubated with 5, 10, or 15 μg/mL SARS-CoV-2 VLPs for 24 h; 50 ng/mL lipopolysaccharide-treated DCs were used as the positive control. The culture supernatants were collected and evaluated for the levels of TNF-α, IL-1β, IL-10, IL-12p70, IFN-γ, and IL-4 using the respective ELISA kit according to the manufacturer’s instructions. The levels of cytokines released into culture medium were determined by measuring OD450 using a microplate reader.
Treatment of DCs with pharmacological inhibitors of signaling pathways
All pharmacological inhibitors (Beyotime Biotechnology, China) were reconstituted in dimethyl sulfoxide (DMSO, Solarbio, China) and used at the following concentrations: U0126 (10 μM), SB203580 (20 μM), and Bay11-7082 (20 μM). DMSO (0.1%) was used as the vehicle control. In experiments with inhibitors, DCs were treated with a given inhibitor for 1 h before treatment with VLPs.
Mixed leukocyte reaction
Syngeneic splenocytes isolated from C57BL/6 mice were lysed using red blood cell lysing buffer (BOSTER, China). After washing twice with PBS, the cells were resuspended in complete RPMI 1640 (Invitrogen, China) and subsequently used for MLR. To test their allogeneic stimulatory activity, DCs were treated with SARS-CoV-2 VLPs for 48 h and then cocultured with the obtained splenic cells at a ratio of 1:20, 1:40, or 1:80 in 96-well plates for 72 h, followed by incubation in 10 μL CCK-8 solution (BOSTER, China) at 37°C for 4 h. OD450 was measured using a microplate reader. SI was calculated using the following formula: SI = (ODsample well − ODblank well)/(ODnegative well − ODblank well).
To further investigate the proliferation of CD4+ and CD8+ T cells in splenocytes, the splenic cells were resuspended in 5 μM carboxyfluorescein diacetate succinimidyl ester (CFSE, Beyotime Biotechnology, China) in DMSO for 10 min at room temperature. DCs (5 × 104 cells/well), treated with 10 μg/mL VLPs for 48 h, were cocultured with the CFSE-labeled autologous naive T cells (1 × 106 cells) derived from spleens at a ratio of 1:20 in 12-well plates for 72 h, and the culture supernatants were collected for cytokine analysis. The cocultured cells were collected and stained with PE-conjugated anti-CD4 and PerCP-conjugated anti-CD8 antibodies (ThermoFisher Scientific, USA). Then, CD4+ and CD8+ T cell proliferation was assessed via the flow cytometric analysis of CFSE dilution of T cells.
Statistical analyses
All experiments were repeated three times. The levels of significance for comparison between the samples were determined via Bonferroni’s multiple comparison test distribution using a statistical software (GraphPad Prism 9.0, San Diego, CA, USA). The data in the graphs are expressed as mean ± standard error. *P < 0.05 or **P < 0.01 denotes statistical significance.
Results
Preparation of SARS-CoV-2 VLPs
SARS-CoV-2 VLPs were prepared according to our previous study [23]. For the expression of the E, M, and S proteins of SARS-CoV-2, the codon-optimized S, E, and M genes of SARS-CoV-2 (GenBank accession no. MN908947.3) were inserted into the pFastBac expression vector (Figure 1A). SARS-CoV-2 VLPs were then produced in insect cells using the Bac-to-Bac system. Using transmission electron microscopy, VLP morphology was observed. As shown in Figures 1B, C, VLP appeared as spherical particles with a diameter of approximately 100 nm, similar to the native SARS-CoV-2.
Figure 1
Cytotoxicity of SARS-CoV-2 VLPs
To investigate the cytotoxicity of SARS-CoV-2 VLPs against DCs, DCs were collected and incubated with SARS-CoV-2 VLPs at different time points. Cell viability was assessed using Annexin V and propidium iodide staining at different time points. As shown in Figure 2A, compared with the control, VLPs of up to 15 μg/mL concentration displayed no cellular toxicity against DCs. Moreover, the particles could induce DC proliferation (Figure 2B).
Figure 2
SARS-CoV-2 VLPs induce DC maturation
To investigate the effect of SARS-CoV-2 VLPs on the maturation of DCs, the phenotypic alteration and cytokine secretion of DCs were evaluated. The results showed that VLP-treated DCs had increased levels of costimulatory molecules (such as CD80 and CD86) and cell surface markers (such as MHC class II) (Figure 3A). As various cytokines secreted by DCs have effects on DC maturation and T cell polarization, the levels of several immunomodulatory cytokines secreted by DCs, including TNF-α, IL-1β, IL-12p70, and IL-10, were investigated. The results revealed that SARS-CoV-2 VLPs induced DCs to secrete TNF-α, IL-1β, IL-10, and IL-12p70 (Figure 3B).
Figure 3
In many cases, pathogen recognition and uptake are accompanied by the maturation of DCs; the endocytic capacity of DCs is downregulated during their maturation, and immature DCs have a higher antigen endocytic capacity than mature DCs (Guermonprez et al., 2002). Therefore, the influence of SARS-CoV-2 VLPs on the endocytic capacity of DC was evaluated using the dextran–FITC uptake experiment. Dextran–FITC is mainly absorbed by the mannose receptor, a commonly used model substrate for studying pinocytosis and phagocytosis (Sallusto et al., 1995; Monti et al., 2003). DCs incubated with dextran–FITC at 37°C accumulated this marker in a time-dependent manner and can be detected by flow cytometry (Sallusto et al., 1995). The flow cytometry analysis revealed that SARS-CoV-2 VLP-treated DCs had reduced endocytic capacity, which was expected for mature DCs (Figure 4).
Figure 4
In the present study, after the interaction between DCs and SARS-CoV-2 VLPs, DCs downregulated the antigen uptake capacity, increased surface molecule expression, and secreted cytokines. These results suggest that immature DCs become mature after undergoing phenotypic and functional changes and that SARS-CoV-2 VLPs are potent inducers of DC maturation.
SARS-CoV-2 VLPs activate DCs via the mitogen-activated protein kinase and nuclear factor- κB signaling pathways
NF-κB and MAPKs play a crucial role in DC maturation (Rescigno et al., 1998). Whether SARS-CoV-2 VLPs activate MAPKs and NF-κB in DCs was then investigated. U0126 permeabilizes cells and specifically inhibits the ability of mitogen-activated protein kinase/ERK kinase (MEK) to phosphorylate extracellular signal-regulated kinase (ERK) without affecting the p38 and Jun NH2-terminal kinase (JNK) pathways (DeSilva et al., 1998). SB 203580 is a widely used specific inhibitor of p38 MAPK that subsequently inhibits the activation of mitogen activated protein kinase-activated protein kinase (MAPKAP kinase)-2 and MAPKAP kinase-3 (Hashimoto et al., 1999). BAY 11-7082, a known NF-κB inhibitor, antagonizes IκB kinase β and prevents the nuclear translocation of NF-κB (Kim et al., 2015; Irrera et al., 2017). In the present study, DCs were pretreated with the ERK1/2 inhibitor U0126, the p38 inhibitor SB203580, and the NF-κB inhibitor Bay11-7082 and subsequently stimulated with SARS-CoV-2 VLPs. DC maturation was evaluated by measuring surface markers and inflammatory cytokines, and the results revealed that U0126, SB203580, and Bay11-7082 significantly downregulated the SARS-CoV-2 VLP-induced expression of the DC maturation markers CD80 and CD86 (Figure 5A). In addition, the VLP-induced expression of TNF-α, IL-1β, IL-12p70, and IL-10 by DCs was markedly reduced after pretreatment with the pharmacological inhibitors (Figure 5B). These results indicated that SARS-CoV-2 VLPs activated the MAPK and NF-κB signaling pathways and that these signaling pathways play a crucial role in DC maturation.
Figure 5
SARS-CoV-2 VLPs promote naive T cell proliferation
Mature DCs have the ability to activate antigen-specific naive T cells to initiate adaptive immune responses (Stockwin et al., 2000). To investigate whether SARS-CoV-2 VLPs can induce DC maturation and promote naive T cell proliferation, MLR assay was performed. The splenocytes of C57BL/6 mice were cocultured with SARS-CoV-2 VLP-treated DCs, and the results showed that SARS-CoV-2 VLP-treated DCs enhanced the proliferation of splenocytes. Of note, cell proliferation was negatively correlated with VLP concentration (Figure 6A). CFSE can be used to monitor the number of T cell divisions during proliferation, which was assessed using flow cytometry (Hawkins et al., 2007). DCs treated with SARS-CoV-2 VLPs at low concentrations, but not at high concentrations, promoted the proliferation of CD8+ and CD4+ T cells (Figure 6B). These results suggest that VLPs provide a potent stimulus for the proliferation of CD8+ and CD4+ T cells via DC activation. Cytokine production was also evaluated under MLR conditions, which showed that a higher level of IFN-γ was produced by T cells primed with SARS-CoV-2 VLP-treated DCs (Figure 6C). This result indicated that mature DCs induced by SARS-CoV-2 VLPs drive T cell polarization toward the Th1 phenotype.
Figure 6
Discussion
SARS-CoV-2 is the causative agent of COVID-19 (Zhu et al., 2020). However, few functional interactions have been identified between the host cells and SARS-CoV-2. DCs are professional antigen-presenting cells with a unique ability to initiate and regulate cell-mediated immune responses. While the key importance of DCs in coronavirus diseases has been reported (Marzi et al., 2004; Cervantes-Barragan et al., 2007; Yoshikawa et al., 2009; Law et al., 2009; Chu et al., 2014; Chang et al., 2022), its role in the pathogenesis of COVID-19 has not been sufficiently studied. In the present study, the functional roles mediated by SARS-CoV-2 VLPs in their interaction with DCs were evaluated.
Studies have shown that exogenous signaling induces DCs to downregulate antigen uptake and upregulate maturation markers (De Smedt et al., 1996; Banchereau et al., 2000; Manickasingham and Reis e Sousa, 2000). The upregulation of certain molecules, including MHC, CD40, CD80, CD83, and CD86, correlates with T cell-priming ability (Banchereau et al., 2000). The exposure of DCs to the infectious SARS-CoV leads to the phenotypic maturation of DCs, with the increased expression of MHC-II and costimulatory molecules (Tseng et al., 2005). SARS-CoV VLPs have also been shown to induce higher levels of CD83, CD40, CD86, and CD80 expression on DCs (Bai et al., 2008). In line with these studies, the present study results demonstrated that SARS-CoV-2 VLPs induce DC to downregulate dextran–FITC uptake and upregulate CD80, CD86, and MHC-II surface markers (Figures 4, 3A).
DC maturation results in proinflammatory cytokine production that can subsequently activate innate and adaptive immune responses as well as mediate immunopathology (Liu, 2022). MERS-CoV-infected monocyte-derived DCs highly expressed IFN, IFN-inducible protein 10 (IP-10), IL-12, and RANTES (Chu et al., 2014). After abortive infection with SARS-CoV, DCs upregulated the expression of chemokines IP-10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1α, and RANTES (Chen and Subbarao, 2007). Incubating DCs with SARS-CoV VLPs significantly enhanced the expression levels of IL-6, IL-10, and TNF-α (Liu, 2022). The present study showed that SARS-CoV-2 VLP-induced DCs increased the production of TNF-α, IL-1β, IL-12p70, and IL-10 (Figure 3B).
DC maturation is accompanied by downregulated antigen uptake capacity, increased surface molecule expression, and increased cytokines secretion (De Smedt et al., 1996; Banchereau et al., 2000; Manickasingham and Reis e Sousa, 2000; Guermonprez et al., 2002; Liu, 2022). The present study results indicated that SARS-CoV-2 VLPs can interact with DCs to induce DC maturation and activation.
It has been reported that the MAPK and NF-κB signaling pathways are involved in DC maturation (Richards et al., 2002; Byun et al., 2012). In line with these studies, SARS-CoV-2 VLPs significantly increased the expression of surface molecules and proinflammatory cytokine secretion by activating the MAPK and NF-κB signaling pathways (Figure 5). Thus, the study findings indicated that these two signaling pathways are essential for the SARS-CoV-2 VLP-induced maturation of DCs.
Mature DCs induce naive T cell proliferation and differentiate into effector T cells in the lymph nodes (Banchereau and Steinman, 1998). DCs regulate the T cell differentiation process via antigen presentation and by triggering specialized cytokine microenvironments. The differentiation of naive T cells into appropriate T cell subtypes is critical for antiviral immunity. CD4+ and CD8+ T cells are important immune components against intracellular viral infection. CD4+ T cells enhance the antibody and cytotoxic T lymphocyte responses. CD8+ T cells recognize virus-infected cells and eliminate them to limit viral spread (Young, 2022). To precisely characterize the SARS-CoV-2 VLP activity on DC and T cell interactions, the syngeneic MLR assay was performed, which revealed that SARS-CoV-2 VLP treatment enhanced CD4+ and CD8+ T cell proliferation (Figures 6A, B). In addition, T cells cocultured with SARS-CoV-2 VLP-treated DCs increased the expression of IFN-γ but not of IL-4 (Figure 6C). T cell proliferation and IFN-γ production indicated that the SARS-CoV-2 VLP-induced maturation of DCs was responsible for presenting the antigens to T cells and influencing the subsequent adaptive immune responses.
In COVID-19, high T cell activity response is associated with milder disease, whereas a poor T cell response is associated with severe disease (Young, 2022). In the present study, interestingly, the proliferation of both CD4+ and CD8+ T cells was negatively correlated with the concentration of VLPs. Thus, the impact of changes in the SARS-CoV-2 viral load on DC–T cell interactions may have contributed to the different outcomes of COVID-19, suggesting that the role of DCs in COVID-19 needs to be further clarified.
Taken together, these findings demonstrate that SARS-CoV-2 VLPs can activate DCs and initiate the adaptive immune response. The present study results may contribute to a better understanding of the mechanisms involved in the immune response against SARS-CoV-2 and provide knowledge for the rational design and development of future COVID-19 vaccines.
Funding
This research was funded by the Gansu Science and Technology Project (21JR7RA443), Science and Technology Innovation Project of Gansu Provincial Department of Education (2022B-118), Main Research and Development Program of Gansu Province in 2020 (20YF8FA072), Lanzhou Science and Technology Planning Project (2020-XG-33), Key Laboratory of Dunhuang Medical and Translational Education Ministry Project (DHXY20-08).
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI, GenBank accession no. MN908947.3.
Ethics statement
The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Lanzhou University.
Author contributions
YM and LL contributed to conception and design of the study and wrote the first draft of the manuscript. KX, QL, WW, WD, JD, and YZ carried out the experiments. LL performed the statistical analysis. JT revised the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BaiB.HuQ.HuH.ZhouP.ShiZ.MengJ.et al. (2008). Virus-like particles of sars-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PloS One3 (7), e2685. doi: 10.1371/journal.pone.0002685
2
BanchereauJ.BriereF.CauxC.DavoustJ.LebecqueS.LiuY. J.et al. (2000). Immunobiology of dendritic cells. Annu. Rev. Immunol.18, 767–811. doi: 10.1146/annurev.immunol.18.1.767
3
BanchereauJ.SteinmanR. M. (1998). Dendritic cells and the control of immunity. Nature392 (6673), 245–252. doi: 10.1038/32588
4
ByunE. H.KimW. S.KimJ. S.JungI. D.ParkY. M.KimH. J.et al. (2012). Mycobacterium tuberculosis Rv0577, a novel Tlr2 agonist, induces maturation of dendritic cells and drives Th1 immune response. FASEB J.26 (6), 2695–2711. doi: 10.1096/fj.11-199588
5
Cervantes-BarraganL.ZüstR.WeberF.SpiegelM.LangK. S.AkiraS.et al. (2007). Control of coronavirus infection through plasmacytoid dendritic-Cell-Derived type I interferon. Blood109 (3), 1131–1137. doi: 10.1182/blood-2006-05-023770
6
ChangT.YangJ.DengH.ChenD.YangX.TangZ.-H. (2022). Depletion and dysfunction of dendritic cells: Understanding sars-Cov-2 infection. Front. Immunol.13. doi: 10.3389/fimmu.2022.843342
7
ChenJ.SubbaraoK. (2007). The immunobiology of sars. Annu. Rev. Immunol.25 (1), 443–472. doi: 10.1146/annurev.immunol.25.022106.141706
8
ChungY. H.CaiH.SteinmetzN. F. (2020). Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. Adv. Drug Delivery Rev.S0169-409X (20), 30070–30073. doi: 10.1016/j.addr.2020.06.024
9
ChuH.ZhouJ.WongB. H.LiC.ChengZ. S.LinX.et al. (2014). Productive replication of middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology454-455, 197–205. doi: 10.1016/j.virol.2014.02.018
10
DeSilvaD. R.JonesE. A.FavataM. F.JaffeeB. D.MagoldaR. L.TrzaskosJ. M.et al. (1998). Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J. Immunol.160 (9), 4175–4181.
11
De SmedtT.PajakB.MurailleE.LespagnardL.HeinenE.De BaetselierP.et al. (1996). Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med.184 (4), 1413–1424. doi: 10.1084/jem.184.4.1413
12
GuermonprezP.ValladeauJ.ZitvogelL.ThéryC.AmigorenaS. (2002). Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol.20 (1), 621–667. doi: 10.1146/annurev.immunol.20.100301.064828
13
HashimotoS.MatsumotoK.GonY.FuruichiS.MaruokaS.TakeshitaI.et al. (1999). Thioredoxin negatively regulates P38 map kinase activation and il-6 production by tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun.258 (2), 443–447. doi: 10.1006/bbrc.1999.0658
14
HawkinsE. D.HommelM.TurnerM. L.BattyeF. L.MarkhamJ. F.HodgkinP. D. (2007). Measuring lymphocyte proliferation, survival and differentiation using cfse time-series data. Nat. Protoc.2 (9), 2057–2067. doi: 10.1038/nprot.2007.297
15
HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.et al. (2020). Sars-Cov-2 cell entry depends on Ace2 and Tmprss2 and is blocked by a clinically proven protease inhibitor. Cell181 (2), 271–2808. doi: 10.1016/j.cell.2020.02.052
16
InabaK.InabaM.RomaniN.AyaH.DeguchiM.IkeharaS.et al. (1992). Generation of Large numbers of dendritic cells from mouse bone marrow cultures supplemented with Granulocyte/Macrophage colony-stimulating factor. J. Exp. Med.176 (6), 1693–1702. doi: 10.1084/jem.176.6.1693
17
IrreraN.VaccaroM.BittoA.PallioG.PizzinoG.LentiniM.et al. (2017). Bay 11-7082 inhibits the nf-Kb and Nlrp3 inflammasome pathways and protects against imq-induced psoriasis. Clin. Sci. (Lond)131 (6), 487–498. doi: 10.1042/cs20160645
18
KimH. R.ShinD. Y.ChungK. H. (2015). The role of nf-Kb signaling pathway in polyhexamethylene guanidine phosphate induced inflammatory response in mouse macrophage Raw264.7 cells. Toxicol. Lett.233 (2), 148–155. doi: 10.1016/j.toxlet.2015.01.005
19
LawH. K. W.CheungC. Y.SiaS. F.ChanY. O.PeirisJ. S. M.LauY. L. (2009). Toll-like receptors, chemokine receptors and death receptor ligands responses in sars coronavirus infected human monocyte derived dendritic cells. BMC Immunol. SCIIF 310, 35. doi: 10.1186/1471-2172-10-35
20
LeeS. J.ShinS. J.LeeS. J.LeeM. H.KangT. H.NohK. T.et al. (2014). Mycobacterium abscessus Mab2560 induces maturation of dendritic cells Via toll-like receptor 4 and drives Th1 immune response. BMB Rep.47 (9), 512–517. doi: 10.5483/bmbrep.2014.47.9.001
21
LiuY. J. (2022). Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell106 (3), 259–262. doi: 10.1016/s0092-8674(01)00456-1
22
MangalmurtiN.HunterC. A. (2020). Cytokine storms: Understanding covid-19. Immunity53 (1), 19–25. doi: 10.1016/j.immuni.2020.06.017
23
ManickasinghamS.Reis e SousaC. (2000). Microbial and T cell-derived stimuli regulate antigen presentation by dendritic cells in vivo. J. Immunol.165 (9), 5027–5034. doi: 10.4049/jimmunol.165.9.5027
24
MaY.NolteR. J. M.CornelissenJ. J. L. M. (2012). Virus-based nanocarriers for drug delivery. Adv. Drug Delivery Rev.64 (9), 811–825. doi: 10.1016/j.addr.2012.01.005
25
MarziA.GrambergT.SimmonsG.MöllerP.RennekampA. J.KrumbiegelM.et al. (2004). Dc-sign and dc-signr interact with the glycoprotein of marburg virus and the s protein of severe acute respiratory syndrome coronavirus. J. Virol.78 (21), 12090–12095. doi: 10.1128/jvi.78.21.12090-12095.2004
26
MiY.XieT.ZhuB.TanJ.LiX.LuoY.et al. (2021). Production of sars-Cov-2 virus-like particles in insect cells. Vaccines9 (6), 554. doi: 10.3390/vaccines9060554
27
MohsenM. O.AugustoG.BachmannM. F.MohsenM. O.AugustoG.BachmannM. F. (2020). The 3ds in virus-like particle based-vaccines: "Design, delivery and dynamics". Immunol. Rev296(1), 155–168. doi: 10.1111/imr.12863
28
MontiP.MercalliA.LeoneB. E.ValerioD. C.AllavenaP.PiemontiL. (2003). Rapamycin impairs antigen uptake of human dendritic cells. Transplantation75 (1), 137–145. doi: 10.1097/00007890-200301150-00025
29
MortolaE.RoyP. (2004). Efficient assembly and release of sars coronavirus-like particles by a heterologous expression system. FEBS Lett.576 (1-2), 174–178. doi: 10.1016/j.febslet.2004.09.009
30
PlesciaC. B.DavidE. A.PatraD.SenguptaR.AmiarS.SuY.et al. (2020). Sars-Cov-2 viral budding and entry can be modeled using bsl-2 level virus-like particles. J. Biol. Chem.296, 100103. doi: 10.1074/jbc.RA120.016148
31
RescignoM.MartinoM.SutherlandC. L.GoldM. R.Ricciardi-CastagnoliP. (1998). Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med.188 (11), 2175–2180. doi: 10.1084/jem.188.11.2175
32
RichardsJ.Le NaourF.HanashS.BerettaL. (2002). Integrated genomic and proteomic analysis of signaling pathways in dendritic cell differentiation and maturation. Ann. NY Acad. Sci.975, 91–100. doi: 10.1111/j.1749-6632.2002.tb05944.x
33
RoldãoA.MelladoM. C. M.CastilhoL. R.CarrondoM. J. T.AlvesP. M. (2010). Virus-like particles in vaccine development. Expert Rev. Vaccines9 (10), 1149–1176. doi: 10.1586/erv.10.115
34
SallustoF.CellaM.DanieliC.LanzavecchiaA. (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class ii compartment: Downregulation by cytokines and bacterial products. J. Exp. Med.182 (2), 389–400. doi: 10.1084/jem.182.2.389
35
Sánchez-CerrilloI.LandeteP.AldaveB.Sánchez-AlonsoS.Sánchez-AzofraA.Marcos-JiménezA.et al. (2020). Covid-19 severity associates with pulmonary redistribution of Cd1c+ dcs and inflammatory transitional and nonclassical monocytes. J. Clin. Invest.130 (12), 6290–6300. doi: 10.1172/jci140335
36
SiuY. L.TeohK. T.LoJ.ChanC. M.KienF.EscriouN.et al. (2008). E, and n structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J. Virol.82 (22), 11318–11330. doi: 10.1128/jvi.01052-08
37
SousaC. R. E. (2006). Dendritic cells in a mature age. Nat. Rev. Immunol.6 (6), 476–483. doi: 10.1038/nri1845
38
SousaC. R. E. (2022). Dendritic cells as sensors of infection. Immunity14 (5), 495–498. doi: 10.1016/s1074-7613(01)00136-4
39
StockwinL. H.McGonagleD.MartinI. G.BlairG. E. (2000). Dendritic cells: Immunological sentinels with a central role in health and disease. Immunol. Cell Biol.78 (2), 91–102. doi: 10.1046/j.1440-1711.2000.00888.x
40
SwensonD. L.WarfieldK. L.KuehlK.LarsenT.HeveyM. C.SchmaljohnA.et al. (2004). Generation of marburg virus-like particles by Co-expression of glycoprotein and matrix protein. FEMS Immunol. Med. Microbiol.40 (1), 27–31. doi: 10.1016/s0928-8244(03)00273-6
41
TsengC.-T. K.PerroneL. A.ZhuH.MakinoS.PetersC. J. (2005). Severe acute respiratory syndrome and the innate immune responses: Modulation of effector cell function without productive infection. J. Immunol. SWJTU A+SCIIF 5174 (12), 7977–7985. doi: 10.4049/jimmunol.174.12.7977
42
WangC.ZhengX.GaiW.ZhaoY.WangH.WangH.et al. (2017). Mers-cov virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget8 (8), 12686–12694. doi: 10.18632/oncotarget.8475
43
XiongY.LiuY.CaoL.WangD.GuoM.JiangA.et al. (2020). Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in covid-19 patients. Emerging Microbes Infect.9 (1), 761–770. doi: 10.1080/22221751.2020.1747363
44
YillaM.HarcourtB. H.HickmanC. J.McGrewM.TaminA.GoldsmithC. S.et al. (2005). Sars-coronavirus replication in human peripheral Monocytes/Macrophages. Virus Res.107 (1), 93–101. doi: 10.1016/j.virusres.2004.09.004p
45
YoshikawaT.HillT.LiK.PetersC. J.TsengC.-T. K. (2009). Severe acute respiratory syndrome (Sars) coronavirus-induced lung epithelial cytokines exacerbate sars pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol.83 (7), 3039–3048. doi: 10.1128/jvi.01792-08
46
YoungA. (2022). T Cells in sars-Cov-2 infection and vaccination. Ther. Adv. Vaccines Immunotherapy10, 1–20. doi: 10.1177/25151355221115011
47
Zepeda-CervantesJ.Ramírez-JarquínJ. O.VacaL. (2020). Interaction between virus-like particles (Vlps) and pattern recognition receptors (Prrs) from dendritic cells (Dcs): Toward better engineering of vlps. Front. Immunol.11. doi: 10.3389/fimmu.2020.01100
48
ZhuN.ZhangD.WangW.LiX.YangB.SongJ.et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N Engl. J. Med.382 (8), 727–733. doi: 10.1056/NEJMoa2001017
Summary
Keywords
SARS-CoV-2, COVID-19, virus-like particles (VLPs), dendritic cells, T cell
Citation
Mi Y, Liang L, Xu K, Li Q, Wang W, Dang W, Deng J, Zhi Y, Li X and Tan J (2022) Severe acute respiratory syndrome coronavirus 2 virus-like particles induce dendritic cell maturation and modulate T cell immunity. Front. Cell. Infect. Microbiol. 12:986350. doi: 10.3389/fcimb.2022.986350
Received
05 July 2022
Accepted
24 October 2022
Published
09 November 2022
Volume
12 - 2022
Edited by
Purnima Dubey, The Ohio State University, United States
Reviewed by
Juan A. More-Bayona, National University of San Marcos, Peru; Martin DSouza, Mercer University, United States
Updates
Copyright
© 2022 Mi, Liang, Xu, Li, Wang, Dang, Deng, Zhi, Li and Tan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Youjun Mi, miyoujun@126.com; Jiying Tan, tanjy@lzu.edu.cn
†These authors have contributed equally to this work and share first authorship
This article was submitted to Virus and Host, a section of the journal Frontiers in Cellular and Infection Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.